Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 116 points (0.8%) at 15,038 as of Monday, Sept. 9, 2013, 12:44 PM ET. The NYSE advances/declines ratio sits at 2,262 issues advancing vs. 646 declining with 106 unchanged. The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 11.5%, Incyte ( INCY), up 5.5% and Novo Nordisk A/S ( NVO), up 1.5%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Sanofi ( SNY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.46 (-0.9%) to $48.30 on light volume. Thus far, 508,811 shares of Sanofi exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $47.93-$48.37 after having opened the day at $48.09 as compared to the previous trading day's close of $48.76. Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $127.5 billion and is part of the health care sector. Shares are up 2.9% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.